148 related articles for article (PubMed ID: 21723597)
21. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
22. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
23. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
Dy GK; Hillman SL; Rowland KM; Molina JR; Steen PD; Wender DB; Nair S; Mandrekar S; Schild SE; Adjei AA;
Cancer; 2010 Dec; 116(24):5686-93. PubMed ID: 21218460
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gold MA; Brady WE; Lankes HA; Rose PG; Kelley JL; De Geest K; Crispens MA; Resnick KE; Howell SB
Gynecol Oncol; 2012 Jun; 125(3):635-9. PubMed ID: 22446624
[TBL] [Abstract][Full Text] [Related]
25. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
El-Khoueiry AB; Rankin CJ; Ben-Josef E; Lenz HJ; Gold PJ; Hamilton RD; Govindarajan R; Eng C; Blanke CD
Invest New Drugs; 2012 Aug; 30(4):1646-51. PubMed ID: 21748296
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Lee JM; Sarosy GA; Annunziata CM; Azad N; Minasian L; Kotz H; Squires J; Houston N; Kohn EC
Br J Cancer; 2010 Feb; 102(3):495-9. PubMed ID: 20051952
[TBL] [Abstract][Full Text] [Related]
27. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT; Ringel MD; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH
J Clin Oncol; 2009 Apr; 27(10):1675-84. PubMed ID: 19255327
[TBL] [Abstract][Full Text] [Related]
30. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract][Full Text] [Related]
31. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Di Lorenzo G; Cartenì G; Autorino R; Bruni G; Tudini M; Rizzo M; Aieta M; Gonnella A; Rescigno P; Perdonà S; Giannarini G; Pignata S; Longo N; Palmieri G; Imbimbo C; De Laurentiis M; Mirone V; Ficorella C; De Placido S
J Clin Oncol; 2009 Sep; 27(27):4469-74. PubMed ID: 19652053
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
35. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
[TBL] [Abstract][Full Text] [Related]
36. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Dubey S; Jänne PA; Krug L; Pang H; Wang X; Heinze R; Watt C; Crawford J; Kratzke R; Vokes E; Kindler HL
J Thorac Oncol; 2010 Oct; 5(10):1655-61. PubMed ID: 20736856
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Eisen T; Oudard S; Szczylik C; Gravis G; Heinzer H; Middleton R; Cihon F; Anderson S; Shah S; Bukowski R; Escudier B;
J Natl Cancer Inst; 2008 Oct; 100(20):1454-63. PubMed ID: 18840822
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Ahmed M; Barbachano Y; Riddell A; Hickey J; Newbold KL; Viros A; Harrington KJ; Marais R; Nutting CM
Eur J Endocrinol; 2011 Aug; 165(2):315-22. PubMed ID: 21566072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]